In northern Nigeria, a focus group discussion with 13 senior Islamic scholars (Imams) from diverse ideological backgrounds was conducted in Gombe one week before the state’s HPV vaccine launch in May 2024, with the aim of surfacing barriers to vaccine acceptance and building religious endorsement ahead of rollout. Scholars reached consensus that Islam permits — […]
Topic: Single Dose Implementation
HPV Vaccination PHPV Vaccination Determinant in Cameroon: A Cross-Sectional Nationwide Health Workers Survey
In Cameroon, HPV vaccination coverage remained below 20% until 2023, when the introduction of a single-dose gender-neutral schedule combined with periodic intensification of routine immunisation (PIRI) raised coverage to approximately 60% among girls. A nationwide cross-sectional survey of 1,225 health workers conducted between August 2023 and July 2024 found that 83% were willing to vaccinate […]
Financing and Policy Dynamics in HPV Vaccine Uptake: Insights from Kenya’s Gavi Transition and Single-Dose Introduction
In Kenya, a retrospective analysis of HPV Dose 1 data from the national health information system (2019–2025) reveals a pronounced cyclical uptake pattern, with quarterly doses ranging from a low of 21,764 (Q1 2025) to a peak of 564,403 (Q4 2021), with surges consistently linked to intensified outreach campaigns and school calendar alignment and sharp […]
Does a single-dose HPV vaccine regimen deliver program cost savings? Real-world evidence from Ethiopia
In Ethiopia, a retrospective microcosting study of the late 2024 HPV vaccine multi-age cohort (MAC) campaign — targeting girls aged 9–14 across 82 health facilities in four regions — estimated the financial cost of delivering a single dose at US$0.66 and the economic cost at US$1.67 per fully vaccinated girl, excluding vaccine and immunization supply […]
Leaving 22 million girls unprotected from HPV: Impact of adopting a single-age target with low vaccination coverage in Kenya
In Kenya, a static cohort modelling study evaluated 12 HPV vaccination policy scenarios to inform the country’s cervical cancer elimination trajectory toward 2030. A prompt switch to a single-dose strategy combined with rapid coverage scale-up would avert an additional 249,700 DALYs compared with the current two-dose programme at approximately 50% coverage, while simultaneously reducing both […]
Policy, Schedule and Vaccine Product Choice: Q&A Session
The Q&A session highlighted critical considerations for transitioning to single-dose HPV vaccination, including evidence needs for NITAG decision-making, updates on ongoing trials like HANDS, and the unique immunological advantages of virus-like particle vaccines. Participants raised concerns about vaccine efficacy in older adolescents, genotype distribution differences (e.g., HPV 52 prevalence), and implications for vaccine selection. Discussions […]
Decision-making to switch to single dose
The presentation outlines Myanmar’s policy shift from a two-dose to a single-dose HPV vaccination schedule, driven by operational challenges during COVID-19, missed cohorts, and WHO’s updated recommendations. NITAG adopted a systematic, evidence-based approach using PICO criteria to guide decision-making, ensuring transparency and technical rigor. The revised strategy targets 9–11-year-old girls through school and community campaigns, […]
Stratégie d’administration du vaccin contre le virus du papillome humain au Cameroun : Progrès avec le protocole à dose unique non genré trois ans après son introduction.
Ce poster analyse l’évolution de la stratégie de vaccination contre le HPV au Cameroun depuis son introduction en 2020, marquée par une faible couverture initiale. L’adoption en 2023 d’un protocole à dose unique et non sexiste, associé à des campagnes intensifiées et à une forte mobilisation communautaire, a permis de tripler la couverture vaccinale. L’expérience […]
Prise de décision, planification et mise en oeuvre (y compris la couverture) de la dose unique: Expérience du Cameroun
Le programme de vaccination contre le HPV au Cameroun a rencontré d’importants défis à son lancement, notamment l’insécurité, la désinformation et l’opposition religieuse, limitant la couverture initiale à moins de 20 %. Initialement mis en œuvre avec un schéma à deux doses en 2020, le pays est passé en 2022 à une stratégie à dose […]
Expérience de prise de décision et de mise en oeuvre d’une dose unique – Seance Questions-Reponses
La séance de discussion a mis en lumière des questions opérationnelles et stratégiques autour de l’introduction du schéma monodose et de la vaccination neutre en termes de genre. Les participants (Nigéria, Cameroun, Togo, Cabo Verde) ont abordé les écarts de couverture entre filles et garçons, l’acceptabilité sociale de vacciner les garçons et les obstacles culturels […]